— Mallinckrodt plc (NYSE: MNK) reported fourth-quarter 2019 earnings of $2.40 per share, vs. $2.05 per share expected.
— Q4 net sales fell 3.6% to $804.9 million, vs. $772.5 million expected. The topline was helped by strong performance across hospital products and the Specialty Generics segment.
— Company says it has reached an agreement for a global settlement with a broad-based group of plaintiffs that would resolve all opioid-related claims. It would also take actions to address near-term maturities to strengthen capital structure.
— MNK shares jumped over 20% immediately following the announcement.
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company